Literature DB >> 29466691

Role of production of type I interferons by B cells in the mechanisms and pathogenesis of systemic lupus erythematosus.

Jennie A Hamilton1, Hui-Chen Hsu1, John D Mountz1.   

Abstract

Type I interferons (IFNs) have a prominent role in many aspects of normal innate and adaptive immunity and autoimmunity. However, cell-type specific information about type I IFN expression and autocrine/paracrine signaling is sparse and mostly focused on non-lymphocyte and non-immune cell populations. A major function of B cells is cytokine production, but surprisingly, type I IFN production by B cells in systemic lupus erythematosus (SLE) has not been thoroughly investigated. This is due, in part, to the established view that plasmacytoid dendritic cells (pDCs) are the primary source of pathogenic type I IFN in lupus. Recent studies, however, have provided evidence to challenge this paradigm. Here, we discuss data supporting a new concept that the production of type I IFN, especially IFNβ, by early stage transitional B cells may be an important source of type I IFN to support autoreactive B cell development in lupus. These findings, if confirmed, may provide a new paradigm in designing and developing more effective therapies for preventing the formation of autoreactive B cells.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29466691

Source DB:  PubMed          Journal:  Discov Med        ISSN: 1539-6509            Impact factor:   2.970


  8 in total

Review 1.  The Plasticity of Newly Formed B Cells.

Authors:  Natalia V Giltiay; Daniela Giordano; Edward A Clark
Journal:  J Immunol       Date:  2019-12-15       Impact factor: 5.422

Review 2.  Emerging concepts of type I interferons in SLE pathogenesis and therapy.

Authors:  Antonios Psarras; Miriam Wittmann; Edward M Vital
Journal:  Nat Rev Rheumatol       Date:  2022-09-12       Impact factor: 32.286

3.  Potential role of viral infection and B cells as a linker between innate and adaptive immune response in systemic lupus erythematosus.

Authors:  Mohadeseh Zarei Ghobadi; Shima Izadi; Majid Teymoori-Rad; Mohammad Farahmand; Sayed-Hamidreza Mozhgani; Negar Labbaf; Fazel Shokri; Sayed Mahdi Marashi
Journal:  Immunol Res       Date:  2021-03-30       Impact factor: 2.829

4.  Gene expression analysis delineates the potential roles of multiple interferons in systemic lupus erythematosus.

Authors:  Michelle D Catalina; Prathyusha Bachali; Nicholas S Geraci; Amrie C Grammer; Peter E Lipsky
Journal:  Commun Biol       Date:  2019-04-23

5.  A comprehensive transcriptomic analysis of alternate interferon signaling pathways in peripheral blood mononuclear cells in rheumatoid arthritis.

Authors:  Liang Han; Shenghao Tu; Pan Shen; Jiahui Yan; Yao Huang; Xin Ba; Tingting Li; Weiji Lin; Huihui Li; Kun Yu; Jing Guo; Ying Huang; Kai Qin; Yu Wang; Zhe Chen
Journal:  Aging (Albany NY)       Date:  2021-08-25       Impact factor: 5.682

6.  Lupus nephritis correlates with B cell interferon-β, anti-Smith, and anti-DNA: a retrospective study.

Authors:  Fatima Alduraibi; Huma Fatima; Jennie A Hamilton; W Winn Chatham; Hui-Chen Hsu; John D Mountz
Journal:  Arthritis Res Ther       Date:  2022-04-18       Impact factor: 5.606

7.  An Anti-Inflammatory Azaphenothiazine Inhibits Interferon β Expression and CXCL10 Production in KERTr Cells.

Authors:  Leon Strzadala; Anna Fiedorowicz; Edyta Wysokinska; Ewa Ziolo; Małgorzata Grudzień; Malgorzata Jelen; Krystian Pluta; Beata Morak-Mlodawska; Michal Zimecki; Wojciech Kalas
Journal:  Molecules       Date:  2018-09-24       Impact factor: 4.411

8.  Preclinical to clinical translation of cenerimod, a novel S1P1 receptor modulator, in systemic lupus erythematosus.

Authors:  Sylvie Froidevaux; Marianne M Martinic; Daniel S Strasser; Virginie Sippel; Estelle Gerossier; Ursula Grieder; Gabin M Pierlot; Andrea Kieninger-Graefitsch; Enrico Vezzali; Anna K Stalder; Bérengère Renault; Jesper Ryge; Aaron Hart; Ulrich Mentzel; Peter M A Groenen; Marcel P Keller; Marten Trendelenburg; Mark J Murphy
Journal:  RMD Open       Date:  2020-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.